Microbiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Microbiology 153 (2007), 4150-4158; DOI  10.1099/mic.0.2007/010041-0
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sterk, M.
Right arrow Articles by Müller, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sterk, M.
Right arrow Articles by Müller, N.
Agricola
Right arrow Articles by Sterk, M.
Right arrow Articles by Müller, N.
Microbiology 153 (2007), 4150-4158; DOI  10.1099/mic.0.2007/010041-0
© 2007 Society for General Microbiology

Characterization of a Giardia lamblia WB C6 clone resistant to the isoflavone formononetin

Maaike Sterk{dagger}, Joachim Müller{dagger}, Andrew Hemphill and Norbert Müller

Institute of Parasitology, University of Berne, Länggass-Strasse 122, CH-3012 Berne, Switzerland

Correspondence
Norbert Müller
nmueller{at}ipa.unibe.ch
Joachim Müller
joachim.mueller{at}ipa.unibe.ch

Giardia lamblia is a common intestinal-dwelling protozoan and causes diarrhoea in humans and animals worldwide. For several years, a small number of drugs such as the 5-nitroimidazole metronidazole (MET) or the thiazolide nitazoxanide (NTZ) have been used for chemotherapy against giardiasis. However, various pre-clinical and clinical investigations revealed that antigiardial chemotherapy may be complicated by emergence of giardial resistance to these drugs. The present study addressed the question if isoflavones with antigiardial activity, such as daidzein (DAI) or formononetin (FOR), may serve as alternative compounds for treatment of giardiasis. For this purpose, the potential of G. lamblia clone WB C6 to form resistance to FOR and related isoflavones was tested in vitro. In the line of these experiments, a clone (C3) resistant to isoflavones, but sensitive to MET and NTZ, was generated. Affinity chromatography on DAI-agarose using cell-free extracts of G. lamblia trophozoites resulted in the isolation of a polypeptide of approximately 40 kDa, which was identified by mass spectrometry as a nucleoside hydrolase (NH) homologue (EAA37551.1). In a nucleoside hydrolase assay, recombinant NH hydrolysed all nucleosides with a preference for purine nucleosides and was inhibited by isoflavones. Using quantitative RT-PCR, the expression of genes that are potentially involved in resistance formation was analysed, namely NH and genes encoding variant surface proteins (VSPs, TSA417). The transcript level of the potential target NH was found to be significantly reduced in C3. Moreover, drastic changes were observed in VSP gene expression. This may indicate that resistance formation in Giardia against isoflavones is linked to, and possibly mediated by, altered gene expression. Taken together, our results suggest FOR or related isoflavones as an alternative antigiardial agent to overcome potential problems of resistance to drugs like MET or NTZ. However, the capacity of Giardia to develop resistance to isoflavones can potentially interfere with this alternative treatment of the disease.


Abbreviations: DAI, daidzein; FOR, formononetin; GEN, genistein; MET, 5-nitroimidazole metronidazole; NH, nucleoside hydrolase; NTZ, thiazolide nitazoxanide; PDI, protein disulfide isomerase; VSPs, variant surface proteins

{dagger}These authors equally contributed to this work.




This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
J. Muller, D. Nillius, A. Hehl, A. Hemphill, and N. Muller
Stable expression of Escherichia coli {beta}-glucuronidase A (GusA) in Giardia lamblia: application to high-throughput drug susceptibility testing
J. Antimicrob. Chemother., December 1, 2009; 64(6): 1187 - 1191.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2007 Society for General Microbiology.